Burrill & Co.’s venture capital group has agreed to provide up to $10 million in debt financing to Acusphere Inc. Acusphere, of Cambridge, Mass. is a specialty pharmaceutical company that develops new drugs and improved formulations of existing drugs. Burrill & Co. is a life sciences company. Burrill’s venture capital funds have more than $950 million under management
Acusphere, Inc. (ACUS.PK) today announced the closing of a definitive agreement with Burrill & Company’s venture capital group to provide up to $10 million in debt financing through the sale of a senior secured note and warrant. Seven Hills Partners, LLC provided financial advisory and investment banking services for this transaction.
The initial tranche will be $5 million and the resulting senior secured note will have a five year term and an interest rate of 10%, compounded annually and accrued on the principal amount of the note payable in cash on the maturity date. Accompanying the note will be a warrant to purchase 83,333,333 common shares at an exercise price of $0.12 per share. The warrant will be exercisable immediately and have a term of 5 years.
Acusphere also has the option to draw on two additional $2.5 million tranches upon filing a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for Imagify™ (Perflubutane Polymer Microspheres) for Injectable Suspension and upon reaching agreement with the United States Food and Drug Administration (FDA) under the Special Protocol Assessment (SPA) process on the design of an FDA-required Phase 3 study demonstrating that stress ultrasound with Imagify has benefits relative to stress ultrasound without Imagify. These tranches will be on similar terms as the initial tranche with the exception of the warrant coverage, which, for each tranche, will be a warrant to purchase 27,777,778 common shares at an exercise price of $0.12 per share.
Special Protocol Assessment
The SPA process creates a written agreement between the FDA and a sponsor concerning the clinical trial design, clinical endpoints and other clinical trial issues that can be used to support regulatory approval of a drug candidate. The process is intended to provide assurance that if the agreed upon clinical trial protocol is followed, the clinical trial endpoints are achieved and there is a favorable risk benefit profile, the data may serve as the primary basis of an efficacy claim in support of a New Drug Application (NDA).
About Acusphere, Inc.
Acusphere (ACUS.PK) is a specialty pharmaceutical company that develops new drugs and improved formulations of existing drugs using its proprietary microsphere technology. We are focused on developing proprietary drugs that can offer significant benefits such as improved safety and efficacy, increased patient compliance, greater ease of use, expanded indications or reduced cost. Our lead product candidate, Imagify™ (Perflubutane Polymer Microspheres) for Injectable Suspension, is a cardiovascular drug for the detection of coronary artery disease, the leading cause of death in the United States, for which a New Drug Application (NDA) was submitted to the U.S. Food & Drug Administration (FDA) in April 2008 and filed in June 2008. Imagify and the Company’s other product candidates were created using proprietary technology that enables Acusphere to control the porosity and size of nanoparticles and microspheres in a versatile manner that allows them to be customized to address the delivery needs of a variety of drugs. For more information about Acusphere visit the Company’s web site (www.acusphere.com).
About Burrill & Company
Founded in 1994, Burrill & Company is a San Francisco-based global leader in life sciences with activities in venture capital, private equity, merchant banking and media. The Burrill family of venture capital funds has over $950 million under management and its merchant banking business is one of the industry leaders in life sciences transactions. Visit http://www.burrillandco.com for more information.